MX340574B - Imidazo pirazinas. - Google Patents

Imidazo pirazinas.

Info

Publication number
MX340574B
MX340574B MX2013010183A MX2013010183A MX340574B MX 340574 B MX340574 B MX 340574B MX 2013010183 A MX2013010183 A MX 2013010183A MX 2013010183 A MX2013010183 A MX 2013010183A MX 340574 B MX340574 B MX 340574B
Authority
MX
Mexico
Prior art keywords
pyrazines
imidazo
compounds
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
MX2013010183A
Other languages
English (en)
Other versions
MX2013010183A (es
Inventor
Thomas Luk Kin-Chun
Soth Michael
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013010183A publication Critical patent/MX2013010183A/es
Publication of MX340574B publication Critical patent/MX340574B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan los compuestos de la fórmula (ver Fórmula) y sus sales farmacéuticas aceptables se describen, así como las composiciones farmacéuticas que contienen dichos compuestos y sus sales farmacéuticas aceptables, y el uso de dichos compuestos y composiciones farmacéuticas para el tratamiento, control o mejora de AML.
MX2013010183A 2011-03-17 2012-03-14 Imidazo pirazinas. MX340574B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453601P 2011-03-17 2011-03-17
PCT/EP2012/054415 WO2012123470A1 (en) 2011-03-17 2012-03-14 Imidazo pyrazines

Publications (2)

Publication Number Publication Date
MX2013010183A MX2013010183A (es) 2013-10-03
MX340574B true MX340574B (es) 2016-07-13

Family

ID=45855775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010183A MX340574B (es) 2011-03-17 2012-03-14 Imidazo pirazinas.

Country Status (11)

Country Link
US (1) US8673905B2 (es)
EP (1) EP2686319B1 (es)
JP (1) JP5796094B2 (es)
KR (1) KR101561756B1 (es)
CN (1) CN103429593B (es)
BR (1) BR112013019160A2 (es)
CA (1) CA2830131A1 (es)
ES (1) ES2590928T3 (es)
MX (1) MX340574B (es)
RU (1) RU2600327C2 (es)
WO (1) WO2012123470A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9653770B2 (en) 2014-10-21 2017-05-16 At&T Intellectual Property I, L.P. Guided wave coupler, coupling module and methods for use therewith
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AU2018253115B2 (en) 2017-04-12 2022-08-11 Edigene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
AU2018350980C1 (en) 2017-10-18 2024-12-12 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
EP4616913A3 (en) * 2018-01-29 2025-12-10 Merck Patent GmbH Gcn2 inhibitors and uses thereof
JP7377207B2 (ja) 2018-01-29 2023-11-09 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CA3146375A1 (en) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents
CN111646978B (zh) * 2020-06-11 2021-12-21 浙江大学 N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用
JP2024501658A (ja) * 2020-12-23 2024-01-15 チルドレンズ ホスピタル メディカル センター 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
CA3226908A1 (en) * 2021-07-30 2023-02-02 Scott Bryan HOYT Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
CA2577947A1 (en) * 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. Novel substituted imidazole derivative
WO2007028051A2 (en) * 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
US20070055743A1 (en) 2005-09-02 2007-03-08 Pirtle Ross M Remote control media player
JP2010500365A (ja) * 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
WO2008047307A1 (en) 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
EP2079746A2 (en) * 2006-11-08 2009-07-22 Schering Corporation Imidazopyrazines as protein kinase inhibitors
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
AR066958A1 (es) * 2007-06-14 2009-09-23 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
EP2300469B1 (en) 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors

Also Published As

Publication number Publication date
JP5796094B2 (ja) 2015-10-21
BR112013019160A2 (pt) 2016-10-04
RU2013142881A (ru) 2015-04-27
RU2600327C2 (ru) 2016-10-20
EP2686319B1 (en) 2016-07-13
HK1187614A1 (zh) 2014-04-11
EP2686319A1 (en) 2014-01-22
US8673905B2 (en) 2014-03-18
ES2590928T3 (es) 2016-11-24
CA2830131A1 (en) 2012-09-20
KR101561756B1 (ko) 2015-10-19
MX2013010183A (es) 2013-10-03
JP2014508180A (ja) 2014-04-03
CN103429593B (zh) 2015-09-09
WO2012123470A1 (en) 2012-09-20
US20120238564A1 (en) 2012-09-20
KR20130133870A (ko) 2013-12-09
CN103429593A (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
IN2014MN02598A (es)
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
IN2015DN01119A (es)
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
IN2014DN09434A (es)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TN2015000034A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
GB201209587D0 (en) Therapeutic compounds
WO2013004995A8 (en) Pyrimidinone compounds and their use
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
PH12015501609A1 (en) Phenicol antibacterials
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
TW201613864A (en) Novel compounds
PH12015501088A1 (en) Dimeric compounds
MX2012008328A (es) Derivados de pirazina.
IN2014DN09347A (es)
WO2014062838A3 (en) Pkm2 modulators and methods for their use
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use

Legal Events

Date Code Title Description
FG Grant or registration